WA-SPIE
8.2.2024 22:02:36 CET | Business Wire | Press release
SPIE, the international society for optics and photonics, held an impactful and vibrant Photonics West last week at San Francisco’s Moscone Center, with 24,000-plus technical professionals registered from more than 70 countries across the international optics and photonics community. The largest annual photonics conference, which ran from 27 January to 1 February, hosted over 1,500 exhibitors, and featured over 5,000 technical presentations across an interactive and engaging week that included BiOS, LASE, OPTO, Quantum West, the BiOS Expo, the Photonics West exhibition, the Quantum West Expo, and the co-located AR|VR|MR conference and exhibition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208158413/en/
SPIE Photonics West 2024 hosted an enthusiastic crowd of optics and photonics professionals at San Francisco's Moscone Center. (Photo: Business Wire)
“Photonics West heralds the beginning of the optics and photonics calendar each year for good reason,” said SPIE CEO Kent Rochford. “The invigorating energy and high levels of enthusiasm throughout the Moscone Center characterized a truly exciting week. AR|VR|MR continues to grow by leaps and bounds, and the addition of a standalone exhibit to the Quantum West program reflects the growing impact of the technology. We were also delighted by the success of our brand-new SPIE Global Business Forum, a packed event that drew top industry executives together for high-level presentations and conversation. Altogether it was a pleasure to be part of the networking, research-sharing, and collaborative discussions among world-leading scientists, engineers, students, and businesspeople and I’m already looking forward to Photonics West 2025.”
As always, the dynamic week showcased the latest innovative technologies and discoveries stemming from a diverse and thriving optics and photonics community, bringing together researchers, innovators, engineers, entrepreneurs, and business leaders from across the globe. Over 100 distinct technical conferences paired perfectly with the four exhibitions held during the week, bringing researchers and companies together to further science, technology, and applications. The week also included a wide range of live product demonstrations on the exhibition floors as well as a job fair.
The inaugural SPIE Global Business Forum was a resounding, sold-out success. With the 16th annual Prism Awards honoring the top new optics and photonics products, and the fast-paced Startup Challenge pitch competition, SPIE Photonics West recognized the best optics and photonics technologies, trends, and entrepreneurial opportunities, while the Quantum West Business Summit featured talks and panels that provided key insights into that expanding commercial ecosystem.
In addition, a program of 56 educational courses offered expert-led technical training and learning, which complemented the dozens of professional development and networking sessions. From Lunch and Learn programming focused on EDI, to networking and social events that provided many opportunities for in-person conversations and possible future collaborations, Photonics West featured a packed calendar of special events.
While the week held myriad opportunities for attendees to learn, network, and share their latest advancements, it was the buzzing exhibitions that best showcased the increasingly vital photonics industry and the importance of in-person meetings.
“The Global Business Forum made it clear that the optics and photonics industry is in the midst of a remarkable era of growth and innovation,” said Stratos Kehayas, PhD, Chief Product & Technology Officer, G&H. “The industry's collective enthusiasm at Photonics West underscores the pivotal role this trade show plays in driving collaboration, fostering innovation, and shaping the future.”
"This has been arguably one of the most productive Photonics Wests we've had in the last five years,” said nLIGHT Vice President and General Manager, Semiconductor Lasers, Matthew Randall. “It’s been very engaging, with lots of people coming through, and we're seeing new things at our booth and at other booths that make this particular show a positive experience. We are definitely seeing way more innovation now than in the last couple of years and that's been incredibly positive not only for nLIGHT, but for the entire photonics industry.”
“The week has been very good,” said MKS Instruments Senior Director of Marketing, Photonics Solutions Division, Vincent M. Issier. “The traffic has been very high and the attendance is incredible this year, and we are very happy with the level of engagement from people here.”
“The week has been great,” said IPG Photonics Director of Product Management, Beam Delivery, UV, Green & Ultrafast Lasers, Mustafa Coskun. “There was nice traffic coming through and it was really nice to connect with colleagues as well as our customers and other visitors. And this is what we're here for: to listen to our customers and understand what their problems are and how we can help them. This Photonics West has been great.”
“This year we were quite busy, even just walking around the show with so many people we know here and so many companies we are in touch with,” said TNO Business Consultant, Optics Manufacturing, Bart Snijders. “It’s great to see them all again. We’ve enjoyed being busy on the floor, busy with meetings. I would always like the show to be six or nine days long, because time is always too short for me here.”
During the Photonics West week, SPIE also announced its latest partnership – this one with The University of Manchester – in the SPIE Endowment Matching Program.
SPIE Photonics West 2025 will take place 25-30 January at the Moscone Center in San Francisco. The call for papers for the 2025 event will open in Spring of 2024.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $24 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208158413/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom